Zoarski G H, Parker J R, Lufkin R B, Harnsberger H R, Rhoda C H
Department of Radiological Sciences, University of California Center for the Health Sciences, Los Angeles 90024-1721.
Invest Radiol. 1992 Aug;27 Suppl 1:S53-7.
This study evaluated the efficacy of gadoteridol in patients with extracranial head and neck pathology.
One hundred twenty-two magnetic resonance imaging (MRI) cases from a multicenter safety and efficacy trial of gadoteridol in patients with suspected head and neck pathology were randomly assigned for evaluation to one of two blinded neuroradiologists.
Enhancement of pathology after gadoteridol injection was noted in 96 cases (78.7%) and provided additional diagnostic information in 57 cases (46.7%). Improved lesion visualization was noted in 37 (64.9%) of these 57 cases; an increase in the number of lesions seen was noted in 4 (7.0%) of 57 cases. Blinded readers determined that additional diagnostic information provided by gadoteridol would have resulted in a change in diagnosis in 20 (35.1%, or 16.4% of total population) of 57 patients.
These results demonstrate that gadoteridol is an efficacious agent for enhanced MRI of head and neck pathology.
本研究评估了钆特醇在颅外头颈部病变患者中的疗效。
在一项钆特醇用于疑似头颈部病变患者的多中心安全性和有效性试验中，将122例磁共振成像（MRI）病例随机分配给两名盲法神经放射科医生中的一位进行评估。
96例（78.7%）患者在注射钆特醇后病变有强化，其中57例（46.7%）提供了额外的诊断信息。这57例中有37例（64.9%）病变可视化得到改善；57例中有4例（7.0%）可见病变数量增加。盲法阅片者判定，钆特醇提供的额外诊断信息会使57例患者中的20例（35.1%，占总人群的16.4%）诊断改变。
这些结果表明钆特醇是头颈部病变增强MRI的有效药物。
